Newsroom

News from UCLB

Subscribe to our RSS News feed
UCLB spinout Freeline Closes $120 Million Series C Financing Round

UCLB spinout Freeline Closes $120 Million Series C Financing Round

/ UCLB News
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases,  announced the closing of a $120 ...
Star Trophies

UCL Business wins in the KE Awards 2020

/ UCLB News
LONDON – 25th June 2020 – UCL Business (UCLB) has won the Knowledge Exchange External Initiative of the Year in ...
COVID-19

UCLTF supports UCL cancer antibody therapies for Covid-19

/ UCLTF News
UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business  (UCLB), has funded UCL’s Cancer Institute in repurposing ...
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

/ Spinout News
Achilles Therapeutics was formed in October 2016 by Syncona Ltd and Cancer Research Technology, with the support of UCLB and ...
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)

Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)

/ Spinout News
BOSTON and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been ...
breathing aid device

UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids

/ UCLB News
Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design ...
AstronauTx secures investment from UCL Technology Fund to further new approaches to dementia therapeutics

AstronauTx secures investment from UCL Technology Fund to further new approaches to dementia therapeutics

/ UCLTF News
London, UK 24 March, 2020 AstronauTx Ltd, a biotech company developing new medicines designed to restore the normal behaviour of ...
Freeline Therapeutics appoints new Chief Medical Officer

Freeline Therapeutics appoints new Chief Medical Officer

/ UCLB News
The biotechnology company focused on developing curative gene therapies for chronic systemic diseases has announced the appointment of Julie Krop ...
Annual Report Front Cover

UCLB Annual Report 2018/19

/ Annual Reports
Download the UCLB Annual Report as a PDF ...
Professor Sergio Quezada appointed as Chief Scientific Officer of Achilles Therapeutics

Professor Sergio Quezada appointed as Chief Scientific Officer of Achilles Therapeutics

/ Spinout News
Achilles Therapeutics has announced the appointment of Professor Sergio Quezada of the UCL Cancer Institute as Chief Scientific Officer with ...
Professor Bobby Gaspar named as the new CEO of Orchard Therapeutics

Professor Bobby Gaspar named as the new CEO of Orchard Therapeutics

/ Spinout News, UCLB News
Congratulations to Professor Bobby Gaspar of the UCL Great Ormond Street Institute of Child Health who has been named the ...
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

BioMarin’s Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

/ UCLB News
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review ...
Star Trophies

Two UCLB spinout companies announced winners at the 2019 SEHTA MedTech Business Awards

/ UCLB News
UCLB spinout companies Odin Vision and Echopoint Medical received awards at the 2019 SEHTA MedTech Business Awards on Thursday 6 ...
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)

/ Spinout News
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD BOSTON ...
Loading...